Talimogene laherparepvec

Generic Name
Talimogene laherparepvec
Brand Names
Imlygic
Drug Type
Biotech
Chemical Formula
-
CAS Number
1187560-31-1
Unique Ingredient Identifier
07730V90L6
Background

Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating...

Indication

This medication is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable, cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery . Elsewhere, the EMA notes that the agent is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly ...

Associated Conditions
Unresectable Skin Lesion
Associated Therapies
-
Clinical Trials
Related News

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

First Posted Date
2017-02-27
Last Posted Date
2023-08-09
Lead Sponsor
Amgen
Target Recruit Count
18
Registration Number
NCT03064763
Locations
🇯🇵

Niigata Cancer Center Hospital, Niigata-shi, Niigata, Japan

🇯🇵

Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan

🇯🇵

National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

and more 6 locations

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

First Posted Date
2016-12-01
Last Posted Date
2024-12-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
68
Registration Number
NCT02978625
Locations
🇺🇸

UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States

and more 33 locations

Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

First Posted Date
2016-11-17
Last Posted Date
2024-11-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
43
Registration Number
NCT02965716
Locations
🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

🇺🇸

University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States

🇺🇸

CTCA at Western Regional Medical Center, Goodyear, Arizona, United States

and more 17 locations

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

First Posted Date
2016-10-05
Last Posted Date
2024-11-15
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
40
Registration Number
NCT02923778
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 14 locations

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

First Posted Date
2016-05-20
Last Posted Date
2024-12-20
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
50
Registration Number
NCT02779855
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Phase 1
Completed
Conditions
Advanced Non CNS Tumors
Interventions
Drug: Talimogene Laherparepvec
First Posted Date
2016-04-29
Last Posted Date
2024-02-20
Lead Sponsor
Amgen
Target Recruit Count
15
Registration Number
NCT02756845
Locations
🇫🇷

Centre Hospitalier Universitaire de Marseille - Hopital de la Timone, Marseille cedex 5, France

🇺🇸

AI Dupont Hospital for Children, Wilmington, Delaware, United States

🇫🇷

Institut Hematologie et Oncologie Pediatrique, Lyon cedex 08, France

and more 19 locations

Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)

First Posted Date
2015-12-10
Last Posted Date
2021-09-08
Lead Sponsor
Amgen
Target Recruit Count
36
Registration Number
NCT02626000
Locations
🇬🇧

Research Site, Wirral, United Kingdom

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

First Posted Date
2015-07-28
Last Posted Date
2024-08-06
Lead Sponsor
Amgen
Target Recruit Count
127
Registration Number
NCT02509507
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

University of California Los Angeles, Santa Monica, California, United States

🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 29 locations

TVEC and Preop Radiation for Sarcoma (4 ml Dose)

First Posted Date
2015-05-25
Last Posted Date
2024-06-20
Lead Sponsor
University of Iowa
Target Recruit Count
30
Registration Number
NCT02453191
Locations
🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

First Posted Date
2015-02-19
Last Posted Date
2021-11-30
Lead Sponsor
Amgen
Target Recruit Count
112
Registration Number
NCT02366195
Locations
🇬🇧

Research Site, Wirral, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy